KR20140128123A - Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides - Google Patents
Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides Download PDFInfo
- Publication number
- KR20140128123A KR20140128123A KR20130046899A KR20130046899A KR20140128123A KR 20140128123 A KR20140128123 A KR 20140128123A KR 20130046899 A KR20130046899 A KR 20130046899A KR 20130046899 A KR20130046899 A KR 20130046899A KR 20140128123 A KR20140128123 A KR 20140128123A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- tobacco
- weight
- present
- inflammatory diseases
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 31
- 230000002265 prevention Effects 0.000 title claims description 10
- 241000253113 Carpesium abrotanoides Species 0.000 title abstract description 7
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 3
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 95
- 244000061176 Nicotiana tabacum Species 0.000 claims description 90
- 244000025254 Cannabis sativa Species 0.000 claims description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 208000012657 Atopic disease Diseases 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 235000013402 health food Nutrition 0.000 claims description 11
- 241000253115 Carpesium Species 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 208000030090 Acute Disease Diseases 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims 5
- 206010034464 Periarthritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 23
- 102000008070 Interferon-gamma Human genes 0.000 abstract description 22
- 229960003130 interferon gamma Drugs 0.000 abstract description 22
- 230000014509 gene expression Effects 0.000 abstract description 15
- 229960003957 dexamethasone Drugs 0.000 abstract description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract description 12
- 102000004127 Cytokines Human genes 0.000 abstract description 9
- 108090000695 Cytokines Proteins 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 5
- 230000002103 transcriptional effect Effects 0.000 abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract description 2
- 235000001497 healthy food Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 108010057466 NF-kappa B Proteins 0.000 description 14
- 102000003945 NF-kappa B Human genes 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 239000002674 ointment Substances 0.000 description 12
- -1 ethyl oleate Chemical class 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 206010057190 Respiratory tract infections Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 2
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229940100608 glycol distearate Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000014828 interferon-gamma production Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000025181 negative regulation of interferon-gamma production Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- AGIQIKMGJVLKMA-NLRWUALESA-N (3ar,4as,5s,5ar,6ar)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one Chemical compound C1[C@@H]2C(=C)C(=O)O[C@@H]2C[C@]2(C)[C@@H](CCC(=O)C)[C@@H]21 AGIQIKMGJVLKMA-NLRWUALESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000385250 Epioblasma triquetra Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- AGIQIKMGJVLKMA-UHFFFAOYSA-N carabrone Natural products C1C2C(=C)C(=O)OC2CC2(C)C(CCC(=O)C)C21 AGIQIKMGJVLKMA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010907 stover Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
The present invention relates to a tobacco plant, The present invention relates to a pharmaceutical composition for preventing and treating atopic and inflammatory diseases,
Activation of NF-κB is regulated at various levels by positive and negative regulatory elements. In resting state, the NF-κB dimer exists in association with IκB for its inhibition. When IκB is phosphorylated by the IκB kinase (IκB kinase) complex, ubiquitination and proteosome degradation proteosomal degradation. Thus, NF-κB migrates to the nucleus, and the migrated NF-κB binds to the NF-κB by immunity, cell differentiation, proliferation, apoptosis, survival response and stress response stress response). In addition, the activity of NF-κB is involved not only in cancer, but also in inflammatory diseases, autoimmune diseases and metabolic diseases.
IFNγ and IL-10 are well-known genes that are induced by NF-κB activity. IFNγ is mainly produced by activated T cells and natural killer cells, which are responsible for innate immunity and adaptive immunity to the intracellular pathogen, and tumor-regulating and immune-stimulatory ) And immune-modulatory effects. IL-10 is a cytokine with anti-inflammatory properties and has a great influence on the development of the immune response. T helper cell tissues composed of
Glucocorticoids are inflammatory diseases such as asthma, rheumatoid arthritis, allergic disease and autoimmune disease associated with overexpression of an inflammatory gene. ≪ / RTI > is generally used for the inhibition of inflammation in various types of inflammatory diseases. Glucocorticoids affect reactive cells due to the activity of the glucocorticoid receptor (GR) in order to directly or indirectly regulate transcriptional regulation of the target gene. GR may be associated with NF-κB by a mechanism similar to direct protein-protein interaction by inhibiting the expression of a range of inflammatory genes.
Psychological problems cause a decrease in natural killer cell (NK cell) activity and non-normal regulation of cytokine stability. NK cell activity responds to the impact of psychological stress, respectively. Psychological distress alters not only the production of interferon gamma (IFN-γ) but also the mode of cytokine production. Glucocorticoid not only reduces the sustained production of cytokines, IL-6, TNF [alpha] and IFN-y, but also reduces the ability of NK cells to bind to tumor targets. However, glucocorticoids do not reduce cytokines, IL-10.
Traditionally, natural products have been used for the treatment of inflammation and other diseases. Aspirin is the most famous natural-derived drug that is commonly used as an anti-inflammatory agent. Other essential anti-inflammatory agents used in asthma control include corticosteroids and salbutamol. In addition, many other natural products such as cyclosporine, mizoribine and FK-506 have shown to inhibit inflammation.
Tobacco Pool ( Carpesium abrotanoides ) are plants belonging to the Campanulales Asteraceae , which grow in the bushes at the edge of forests and are distributed in Korea, China and Japan. The tobacco pool is well known as a "barefoot doctor" and is known to be used as a constitutional remedy, a scurvy remedy, a depurative, a discutient, an emetic, an expectorant, a febrigufe, (laxative) and wound treatment (vulnerary) are known to be effective. Tobacco juice is used to treat bronchitis, tonsillitis, boils, ulcers, and snake bites. The stem juice is used when bitten by insects, and the stem juice is also very effective in the treatment of sore throat.
Accordingly, the inventors of the present invention have been developing a therapeutic agent for inflammatory diseases derived from natural products that can overcome the side effects and limitations of the anti-inflammatory drugs used in the past, abrotanoides) extract the inflammatory cytokine (cytokine) interferon and significantly reduced the expression level of the gamma and IL-10, the conventional anti-inflammatory agent dexamethasone (dexamethasone; when compared with DEX), DEX is present a suppressed only expression of interferon gamma The tobacco grass extract of the present invention is useful as a pharmaceutical composition, an external preparation for skin, a cosmetic composition and a health food composition for preventing or treating atopic and inflammatory diseases by significantly inhibiting the expression of interferon gamma as well as IL-10 The present invention has been completed.
An object of the present invention is snuffbox (Carpesium The present invention also provides a pharmaceutical composition for the prevention and treatment of atopic and inflammatory diseases, which comprises as an active ingredient an abrotanoides extract.
The present invention relates to a tobacco plant, The present invention provides a pharmaceutical composition, an external preparation for skin, a cosmetic composition and a health food composition for the treatment of atopic and inflammatory diseases, which comprises as an active ingredient an abrotanoides extract.
The tobacco plant of the present invention ( Carpesium abrotanoides extract significantly reduced the expression of interferon gamma and IL-10, which are inflammatory cytokines, at the transcriptional level and inhibited only the expression of interferon gamma when compared to the conventional anti-inflammatory agent dexamethasone (DEX) The tobacco grass extract of the present invention is useful as a pharmaceutical composition for preventing or treating atopic and inflammatory diseases, a composition for external application for skin, a cosmetic composition and a health food composition by significantly inhibiting not only interferon gamma but also IL-10 expression Can be used.
Figure 1 is a schematic view of a tobacco plant abrotanoides < / RTI > extract inhibits the production of interferon gamma;
Carpesium: Tobacco grass extract,
Fraction 1:
Fraction 2:
Fraction 3:
Figure 2 shows that the tobacco grass extract inhibits the activity of NF-κB;
Carpesium: Tobacco grass extract.
FIG. 3 shows that tobacco grass extract inhibits mRNA expression of interferon gamma;
Carpesium: Tobacco grass extract, and
DEX: dexamethasone.
Hereinafter, the present invention will be described in detail.
Tobacco Pool ( Carpesium The present invention also provides a pharmaceutical composition for the prevention and treatment of atopic and inflammatory diseases, which comprises as an active ingredient an abrotanoides extract.
The tobacco grass extract and fractions are preferably, but not necessarily, prepared by a process comprising the steps of:
1) extracting with a tobacco extract solution;
2) filtering the extract of step 1);
3) concentrating the filtered extract of step 2) under reduced pressure and then drying to produce an extract of tobacco grass; And
4) Extracting the tobacco grass extract of step 3) with an organic solvent to prepare a tobacco grass fraction.
In the above method, the tobacco plant of step 1) may be used without limitation, such as cultivated or commercially available plants. The tobacco paste may be any of leaves, stems, roots, or flowers, but is not limited thereto.
In the above method, it is preferable to use water, an alcohol or a mixture thereof in the extraction solvent of the step 1). As the alcohol, C 1 to C 2 lower alcohol is preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. It is preferable that the extraction solvent is added by 1 to 10 times the amount of the dried tobacco paste, more preferably by 2 to 3 times. The extraction temperature is preferably 20 占 폚 to 100 占 폚, more preferably 20 占 폚 to 40 占 폚, and most preferably room temperature, but is not limited thereto. The extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. The number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, and most preferably, 3 times, but is not limited thereto.
In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
In the above method, the organic solvent in step 4) is preferably n-hexane, chloroform, ethyl acetate or butanol, but is not limited thereto. The fraction may be n-hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction or water fraction obtained by suspending the tobacco grass extract in water and sequentially fractionating the fraction with n-hexane, chloroform, ethyl acetate, butanol and water But is not limited thereto. The fraction may be obtained by repeating the fractionation process from the tobacco extract at 1 to 5 times, preferably 3 times, followed by fractionation and concentration under reduced pressure. However, the fraction is not limited thereto.
The inflammatory diseases include inflammatory diseases such as dermatitis, conjunctivitis, periodontitis, rhinitis, otitis, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, , Rheumatoid arthritis, shoulder inflammation, tendinitis, hay fever, perianal inflammation, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis and acute and chronic inflammatory diseases But is not limited thereto.
In a specific embodiment of the present invention, the present inventors prepared a tobacco grass extract using a tobacco plant, treated the extracted tobacco grass extract with NK92 cells under various conditions, and then measured the amount of interferon gamma produced using an ELISA kit , It was confirmed that the tobacco grass extract decreased the production of interferon gamma in a concentration-dependent manner (see FIG. 1).
In addition, the present inventors conducted a promoter analysis to confirm whether the result was due to the inhibitory effect of the NF-κB transcription factor on tobacco grass. As a result, the tobacco grass extract inhibited the activity of NF-κB transcription factor Inhibit the production of interferon gamma (see FIG. 2).
In addition, the present inventors confirmed mRNA expression levels to confirm that interferon gamma production inhibition occurs at the transcription level. As a result, it was confirmed that the tobacco grass extract significantly reduced the expression of IFNγ and IL-10 (see FIG. 3).
Accordingly, it has been confirmed that the tobacco grass extract of the present invention significantly inhibits the production of both interferon gamma and IL-10, and thus can be effectively used as a pharmaceutical composition for the treatment and prevention of atopic and inflammatory diseases.
The composition containing the tobacco grass extract of the present invention may further contain at least one active ingredient which exhibits the same or similar function in addition to the above components.
The composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose Starch glycolate, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, calcium stearate, , White sugar, dextrose, sorbitol and talc. The pharmaceutically acceptable additives according to the present invention are preferably included in the composition in an amount of 0.1 to 90 parts by weight, but are not limited thereto.
That is, the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . ≪ / RTI > Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, Sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
The composition of the present invention may be administered orally or parenterally in accordance with the intended method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, . The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.
The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
Specifically, the effective amount of the compound according to the present invention may vary depending on the age, sex, and body weight of the patient. In general, 0.1 mg to 100 mg, preferably 0.5 mg to 10 mg per kg of body weight is administered daily or every other day Or one to three times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
In addition, the present invention provides an external preparation for skin and cosmetic composition for prevention and improvement of atopic and inflammatory diseases containing tobacco grass extract as an active ingredient.
The inventors of the present invention confirmed that the tobacco grass extract of the present invention significantly inhibited the production of both interferon gamma and IL-10, and thus could be effectively used as an external preparation for skin and cosmetic composition for prevention and improvement of atopic and inflammatory diseases .
In addition, the tobacco grass extract of the present invention is preferably used as a raw material for cosmetics, bath products, soaps, pharmaceutical ointments, animal pharmaceuticals or pack products.
That is, the therapeutic agent for atopic and inflammatory diseases containing the tobacco grass extract of the present invention as an active ingredient can be prepared as a solution, a suspension, a spray, a patch, a pad, a cream, an ointment, a gel, a tablet or a pill.
The solution may contain, in addition to the active compound, conventional excipients such as solvents, solubilizers and emulsifiers such as water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, Glycerin, natural corn stover oil, olive oil, castor oil, almond oil and sesame oil, glycerol, glycerol formal alcohol, tetramethyluronium hexafluorophosphate, Fatty acid esters of sorbitan, furfuryl alcohol, polyethylene glycol and sorbitan, or mixtures of these substances, and may contain methyl or propyl-p-hydroxybenzoate or sorbic acid as a preservative.
In addition to the active compound, the suspending agent may contain conventional excipients such as liquid diluents (e.g., water, ethyl alcohol and propylene glycol, polyethylene glycol), and suspending agents (e.g., ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, sorbitan Esters, cellulose derivatives and preservatives for hydrogenation), microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, injectable esters such as ethyl oleate, or mixtures of these substances.
The ointments, creams and gels may contain conventional excipients such as animal and vegetable fats, wax paraffin, starch, targacans, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, ≪ / RTI >
In addition, the administration method can be generally applied to the affected part, and the preferable administration method can be selected according to the formulation.
The daily dose of the composition of the present invention is determined depending on the subject to be administered, method of administration, and symptom, but generally, the tobacco grass extract contained in the composition and the carabrone or its pharmaceutically acceptable salt represented by the formula (1) 100 < RTI ID = 0.0 > pg / ml. ≪ / RTI > The number of times of administration is preferably two times a day or more, but the number of times of administration can also be adjusted depending on the symptom level. However, the dosage needs to be varied and can be varied, in particular considering the sperm specificity and weight of the object to be treated, the type and depth of the disease, the nature of the formulation, the nature of the drug administration, and the duration or interval of administration.
In order to effectively treat atopic and inflammatory diseases, it is important to select a suitable external preparation. In order to treat atopic and inflammatory diseases, tobacco grass extract may be suitably diluted and applied directly to the skin. In the present invention, an ointment agent capable of effectively applying the atopic and inflammatory therapeutic agents to the affected part is provided.
The ointment of the present invention is prepared by combining the above-described therapeutic agent for atopic and inflammatory diseases with an inorganic substance and then coating it with a liposoluble base. The inorganic material is preferably a material having excellent antimicrobial activity, anti-inflammatory effect, epidermal regeneration effect, etc. Specific examples thereof include zinc oxide, zinc carbonate, iron oxide and the like.
In addition, it is preferable to further use a ceramic carrier capable of safely impregnating the atopy of the present invention, which is a water-soluble substance, with a therapeutic agent for inflammatory diseases. As the ceramic carrier, zeolite, talc, gypsum, mortar and mixtures thereof are preferably used. Such a ceramic carrier is excellent in the impregnation property of the water-soluble component, so that the water-soluble component can be smoothly supplied to the skin.
In addition, the present invention provides a health food composition for preventing and ameliorating atopic and inflammatory diseases containing an extract of tobacco grass as an active ingredient.
The inventors of the present invention have confirmed that the tobacco grass extract of the present invention can be effectively used as a health food composition for prevention and improvement of atopic and inflammatory diseases by significantly inhibiting the production of both interferon gamma and IL-10.
The health food of the present invention can be used as it is, or can be used in combination with other food or food ingredients, and can be suitably used according to conventional methods.
There is no particular limitation on the kind of the health food. Examples of the foods to which the tobacco grass extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 of the composition of the present invention.
In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
Hereinafter, the present invention will be described in detail with reference to Examples and Production Examples.
However, the following examples and preparations are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples and production examples.
< Example 1> Tobacco Pool ( Carpesium abrotanoides ) Preparation of extract
Tobacco grass extracts were obtained by pulverizing 200 g of tobacco leaves obtained from China with a pulverizer and then extracting 700 ml of an aqueous methanol solution (80% of methanol and 20% of water). The extract solution was filtered using a filter paper, and the filtered extract was concentrated with a vacuum concentrator to obtain 10 g of tobacco grass extract.
< Example 2> Interferon gamma of tobacco grass extract IFN γ) production inhibitory effect
<2-1> Cell culture
The cultivation of human cell lines (NK 92, NKys, U937) was carried out at 37 ° C in a humidified atmosphere of 5% CO 2 . The blood cell lines NK 92, NKys (human NK cell line) and U937 were purchased from the American Type Culture Collection (ATCC), and the cell lines were cultured in DMEM supplemented with 10% FCS (HyClone, Logan, UT), 2 mM L- glutamate, (Life Technologies, Karlsruhe, Germany) medium containing 100 μg / ml penicillin, 100 μg / ml streptomycin (Life Technologies, Karlsruhe, Germany)
<2-2> Confirmation of inhibitory effect of tobacco grass extract on interferon gamma production
In order to confirm inhibition of interferon gamma production of the tobacco grass extract prepared in Example 1, tobacco grass extract was treated with NK92 cells under various conditions, and the amount of interferon gamma produced was measured using an ELISA kit (BD Biosciences) Respectively.
Specifically, tobacco grass extract was treated with NK92 cell line under various conditions, and the cell line was cultured. Then, 50 μl of the cell culture supernatant was added to an assay plate coated with an antibody recognizing IFNγ, Lt; / RTI > After a period of reaction, an antibody recognizing IFNγ bound to HRP is added and cultured for an additional hour, and the unreacted mixture is washed. The bound enzyme is visualized by the addition of a TMB component to the substrate and the reaction can be stopped by adding 100 μl of 2N H 2 SO 4 . The absorbance was also measured using an ELISA reader (Molecular Devices E max) at 450 nm.
As a result, as shown in Fig. 1, it was confirmed that the tobacco grass extract decreased the production of interferon gamma produced in the activated blood cell NK92 cell line in a concentration-dependent manner (Fig. 1).
< Example 3> Tobacco grass extract NF Inhibitory Effect of -KB Transcription Factor
As a result of the above Example <2-2>, a promoter analysis was performed to determine whether tobacco grass extract was due to the inhibitory effect of NF-κB transcription factor.
Specifically, 1 × 10 5 cells / ml HEK293 cell line was prepared and 1 μg of pGL4.32 [luc2P / NF-κB-RE / Hygro] vector was transfected with a DNA transfection reagent KINOVATE). The transfected cell line was stimulated with 500 ng / ml PMA and serial diluted tobacco grass extract from 10 / / ㎖ to 78 ng / ㎖ was added and cultured for 6 hours. Then, luciferase cell lysis buffer (Promega) was added and stirred at 4 캜 for 30 minutes to obtain a lysate of the stimulated cells. 10 μl of the obtained lysate was transferred to a 96-well luminometer-plate, and 50 μl of Luciferase Assay Substrate (Promega) was added thereto. Lumat Plus LB).
As a result, as shown in FIG. 2, it was confirmed that tobacco grass extract inhibited the production of interferon gamma through inhibition of NF-κB transcription factor activity (FIG. 2). Generally, the production of interferon gamma in immune cells depends on the activity of NF-κB, and the ability of NF-κB to inhibit activity inhibits the activity of pro-inflammatory cytokines.
< Example 4> Interferon gamma of tobacco grass extract and IL -10 mRNA Confirming expression suppression effect
To confirm that the inhibition of interferon gamma production in Example <2-2> occurs at the transcription level, RT-PCR was performed on the NK92 cell line to measure the transcriptional activity of interferon gamma and IL-10.
Specifically, 5 × 10 5 cells / ml of NK92 cells cultured in a 6-well plate containing IL-2 as a growth factor was treated with 500 ng / ml PMA, and then treated with 5, 1, 0.1 μg / ml Of tobacco grass extract was added. After 15 hours of incubation, the stimulated cell lines were collected and pellets were obtained using a micro-centrifuge. A TRIzol solution (MRC) was added to the obtained pellet to isolate the total RNA. A part of the separated total RNA was dried and partially dissolved in 50 μl of diethylene-pyrocarbonate (DEPC). The purified RNA was confirmed to have a high purity using a UV spectrophotometer (Nano Vue). Reverse transcription for synthesis of cDNA was carried out using the first strand cDNA synthesis kit (Promega) reaction was performed according to the manufacturer's instructions using the AccuScript High Accuracy First Strand cDNA Synthesis Kit (AccuScript High Fidelity 1st Strand cDNA Synthesis Kit, Stratagene).
PCR was performed to amplify the synthesized cDNA, and 1 μl of the synthesized cDNA was added to 20 μl of a PCR mixture composed of 0.5 U ExTaq DNA polymerase, 1 × buffer and 1 mM dNTP mix (Takara) and specific primer pairs And the PCR reaction was carried out. The following primers used in the PCR were designed using the
GAPDH_sense (SEQ ID NO: 1): 5'-CCATCACCATCTTCCAGGAG-3 '
GAPDH_antisense (SEQ ID NO: 2): 5'-ACAGTCTTCTGGGTGGCAGT-3 '
IFNgamma_sense (SEQ ID NO: 3): 5'-TGGCTGAACTGTCGCCAGCA-3 '
IFNgamma_antisense (SEQ ID NO: 4): 5'-TGGCTGCCTAGTTGGCCCCT-3 '
IL-10_sense (SEQ ID NO: 5): 5'-TGCCTTCAGCAGAGTGAAGA-3 ', and
IL-10_antisense (SEQ ID NO: 6): 5'-GCCACCCTGATGTCTCAGTT-3 '.
Amplification by PCR reaction was carried out using GeneAmp PCR system 2700 (Applied Biosystems, USA) under the following conditions; After repeating 5 to 9 minutes at 94 ° C, 45 seconds at 94 ° C, 45 seconds at 56 ° C and 25 to 40 times at 72 ° C for 1 minute, the final extension reaction was carried out at 72 ° C for 7 minutes. The PCR products were separated on 1.5% agarose gel, stained with EtBr (ethidium bromide), visualized with a Gel Doc 2000 UV trans-illuminator (UV trans-illuminator, Bio-Rad Laboratories, (Bio-Rad Laboratories, USA). Each sample was tested more than 3 times and representative data were presented.
As a result, as shown in FIG. 3, the expression of IFNγ and IL-10 was significantly reduced when the tobacco grass extract was treated with NK92 cell line, a blood cell. In comparison with DEX, a glucocorticoid, which is used as an inhibitor of NF-κB used as a positive control, and tobacco grass extract of the present invention, similar effects were shown in the inhibition of IFNγ, but glucocorticoids While the tobacco grass extract of the present invention significantly inhibited IL-10 (FIG. 3).
< Manufacturing example 1> Preparation of pharmaceutical preparations
<1-1> Sanje Produce
2 g of the tobacco grass extract of the present invention
Lactose 1 g
The above components were mixed and packed in airtight bags to prepare powders.
<1-2> Preparation of tablets
100 mg of the tobacco grass extract of the present invention
Corn starch 100 mg
100 mg of milk
2 mg of magnesium stearate
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
≪ 1-3 > Preparation of capsules
100 mg of the tobacco grass extract of the present invention
Corn starch 100 mg
100 mg of milk
2 mg of magnesium stearate
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
≪ 1-4 >
1 g of the tobacco grass extract of the present invention
Lactose 1.5 g
Glycerin 1 g
0.5 g of xylitol
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
<1-5> Preparation of granules
150 mg of the tobacco grass extract of the present invention
Soybean extract 50 mg
200 mg of glucose
600 mg of starch
After mixing the above components, 100 mg of 30% ethanol was added and the mixture was dried at 60 캜 to form granules, which were then filled in a capsule.
< Manufacturing example 2> Manufacture of ointment preparation
<2-1> Preparation of liposoluble (W / O formulation) ointment
The tobacco grass extract of the present invention is 0.01 to 10.0%
Stearyl alcohol 7.0%
Stearic acid 2.2%
Squalene 3.4%
Octyl dodecanol 5.0%
Olive oil 6.0%
Glycerin monoauric fatty acid ester 10.0%
Isopropyl adipate 2.0%
Tego 0.3%
Carboxyl vinyl polymer 3.0%
Propylene glycol 5.0%
Kojic acid 0.05%
Alpha-keto glutamic acid 0.2%
Cysteine 0.2%
Parabens 0.3%
Sterile purified water or 0.02 M phosphoric acid or intermediate solution
At the preparation of ointment, the components other than carboxyvinyl polymer and kojic acid were emulsified at 60 ° C or higher in the above composition components, and then carboxyvinyl polymer was added while stirring. After cooling, the remaining aqueous phase components such as kojic acid were slowly added to the mixture to homogeneity when they had a suitable viscosity, and then allowed to stand for maturation before being made into a finished product.
<2-2> Preparation of hydrophilic (W / O type) ointment
The tobacco grass extract of the present invention is 0.01 to 10.0%
White vaseline 25.0%
Stearyl alcohol 20.0%
Propylene glycol 12.0%
Propylene misstatin 0.1%
Sodium glycerin Mono Laurel 0.2%
Polyoxyethylene hardened castor oil 4.0%
Betaine-containing cationic emulsifier 0.2%
Glycerin monostearate 0.1%
0.1% paraoxybenzoic acid propylate
Purified water balance
An ointment type (O / W) ointment agent was prepared by the ointment preparation method of Example <2-1> with the above composition.
<2-3> Preparation of cream
The tobacco grass extract of the present invention is 0.01 to 10.0%
Liquid paraffin 6.0%
Squalane 4.0%
0.5% sorbitan sesquioleate
Polysorbate 60 1.5%
Beeswax 10.0%
Cappolic / capric triglyceride 5.0%
Butylene glycol 6.0%
Free ethanolamine 3.0%
Preservatives 2.0%
Fragrance
Purified water balance
A cream containing the tobacco grass extract in the above composition was prepared according to a conventional method.
< Manufacturing example 3> Cosmetics Preparation of composition
<3-1> Production of cream
0.1 part by weight of tobacco grass extract of the present invention
Cetostearyl alcohol 2.8 parts by weight
2.6 parts by weight
Stearic acid 1.4 parts by weight
≪ tb > < tb >
Sorbitol sesquioleate 1.4 parts by weight
Jojoba oil 4 parts by weight
Squalane 3.8 parts by weight
Polysorbate 60 1.1 parts by weight
Tocopheryl acetate 0.2 part by weight
Methylpolysiloxane 0.4 part by weight
Ethylparaben 0.1 part by weight
Propylparaben 0.1 part by weight
Euxyl K-400 0.1 part by weight
1,3-butylene glycol 7 parts by weight
Methylparaben 0.05 part by weight
Glycerin 6 parts by weight
d-Pandenol 0.2 part by weight
Triethanolamine 0.2 part by weight
pt 41891 0.2 part by weight
Purified water 50.55 parts by weight
<3-2> Production of Lotion
0.1 part by weight of tobacco grass extract of the present invention
Cetostearyl alcohol 1.6 parts by weight
Stearic acid 1.4 parts by weight
Glycerin monostearate of pro-type 1.8 parts by weight
≪ tb > < tb >
Sorbitol sesquioleate 0.6 parts by weight
Squalene 4.8 parts by weight
Tocopheryl acetate 0.4 part by weight
0.2 part by weight of methylpolysiloxane
Ethylparaben 0.1 part by weight
Propylparaben 0.1 part by weight
4 parts by weight of 1,3-butylene glycol
0.1 part by weight of methylparaben
Xanthan gum 0.1 part by weight
Glycerin 4 parts by weight
d-Pandenol 0.15 part by weight
Allantoin 0.1 part by weight
Cargar (2% aq. Sol) 4 parts by weight
Triethanolamine 0.15 part by weight
pt 41891 0.1 part by weight
Purified water 51.7 parts by weight
< Manufacturing example 4> Cosmetics Preparation of cleaning agents in compositions
<4-1> Production of soap
4.0 parts by weight of tobacco grass extract of the present invention
Soap base 94.25 parts by weight
Tocopherol acetate 0.3 part by weight
Glycerin 0.2 part by weight
PEG 4000 (polyethylene glycol 4000) 0.8 parts by weight
Jojoba oil 0.3 part by weight
0.15 parts by weight of cetanol
The components were mixed well in a mixer, extruded in a soap making machine, and cut and molded into a predetermined size to prepare a soap composition. The soap base may be a sodium salt of palm oil, which is a natural oil commonly used in the art.
<4-2> body Cleanser's Produce
4.0 parts by weight of tobacco grass extract of the present invention
Ammonium lauryl sulfate 42 parts by weight
Cocamidopropyl betaine 12 parts by weight
Glycol distearate 0.5 part by weight
Propylene glycol 1.0 part by weight
Pigment amount
Fragrance appropriate amount
Citric acid suitable amount
Drain (50% concentrated liquid) 1.0 part by weight
Purified water is added to make 100 parts by weight.
Ammonium lauryl sulfate, cocamidopropyl betaine, glycol distearate and propylene glycol were heated to 70 ° C and emulsified with heated purified water, and the remaining components were added and cooled to room temperature to prepare a body cleanser.
< Manufacturing example 6> Manufacture of health food
<6-1> Manufacture of Flour Food
0.5 to 5.0 parts by weight of the tobacco grass extract of the present invention was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.
<6-2> soup And juicy ( gravies )
0.1 to 5.0 parts by weight of the tobacco grass extract of the present invention were added to soups and juices to prepare health promotion meat products, noodle soups and juices.
<6-3> Ground Beef Produce
10 parts by weight of the tobacco grass extract of the present invention was added to ground beef to prepare ground beef for health promotion.
<6-4> Dairy products ( dairy products )
5-10 parts by weight of the tobacco grass extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<6-5> Solar Produce
Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
The tobacco grass extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, spray dried, and dried with a hot air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.
The grains, seeds and the tobacco grass extract of the present invention prepared above were blended in the following proportions.
(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
Tobacco grass extract (3 parts by weight) of the present invention,
(0.5 part by weight),
(0.5 parts by weight)
< Manufacturing example 7> Manufacturing of beverages
<7-1> Health drink Produce
(5 g) of the tobacco grass extract of the present invention was uniformly blended with a sub ingredient such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5% And then packaged in small containers such as glass bottles and plastic bottles.
<7-2> Manufacture of vegetable juice
5 g of the tobacco grass extract of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice.
<7-3> Production of fruit juice
1 g of the tobacco grass extract of the present invention was added to 1,000 ml of apple or grape juice to prepare fruit juice.
<110> Korea Research Institute of Bioscience and Biotechnology <120> Method for infinite reproduction of somatic cells for inducing induced pluripotent stem cells by formation of teratoma <130> 13P-02-20 <160> 16 <170> Kopatentin 1.71 <210> 1 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Sox2-F <400> 1 ccatgtatag atctggagga aa 22 <210> 2 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Sox2-R <400> 2 caaatattaa aacttttttt tcatcg 26 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Oct4-F <400> 3 cccaggtccc cactttggca c 21 <210> 4 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Oct4-R <400> 4 acccctgttg tgcttttaat ccc 23 <210> 5 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Nanog-F <400> 5 caccagtgga gtatcccagc at 22 <210> 6 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Nanog-R <400> 6 tggcagagaa gttttgctgc aac 23 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Zfp42-F <400> 7 catcctaacc cacgcaaagg 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Zfp42-R <400> 8 aagagttgca aaattatttt 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FSP-F <400> 9 aggccctgga tgtaattgtg 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FSP-R <400> 10 gctgtccaag ttgctcatca 20 <210> 11 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Fap-F <400> 11 tcaactgtga tggcaagagc 20 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Fap-R <400> 12 catggttctg gtcagagtac 20 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Fap-1F <400> 13 tcaactgtga tggcaagagc 20 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Fap-1R <400> 14 gtaccacatc gcctggaaat 20 <210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH-F <400> 15 ccagtatgac tccactcacg 20 <210> 16 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH-R <400> 16 ttcacaccca tcacaaacat 20
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130046899A KR20140128123A (en) | 2013-04-26 | 2013-04-26 | Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130046899A KR20140128123A (en) | 2013-04-26 | 2013-04-26 | Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140128123A true KR20140128123A (en) | 2014-11-05 |
Family
ID=52452076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20130046899A KR20140128123A (en) | 2013-04-26 | 2013-04-26 | Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20140128123A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220067975A (en) * | 2020-11-18 | 2022-05-25 | 한국과학기술연구원 | Composition for anti-allergy comprising extract of carpesium cernuum |
-
2013
- 2013-04-26 KR KR20130046899A patent/KR20140128123A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220067975A (en) * | 2020-11-18 | 2022-05-25 | 한국과학기술연구원 | Composition for anti-allergy comprising extract of carpesium cernuum |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101364234B1 (en) | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising the extract Daphne genkwa, fraction of thereof or compound isolated therefrom as an active ingredient | |
KR101577111B1 (en) | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction | |
KR102182724B1 (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
KR102334546B1 (en) | Composition for anti-inflammatory comprising male pupa extract | |
KR102448526B1 (en) | A preventing composition comprising CAPE, Quercetin and Chrysin for anti-inflammation | |
KR102315959B1 (en) | A composition for reinforcing immune function comprising the extract of oat sprout | |
KR101487065B1 (en) | A pharmaceutical composition for prevention or treatment of inflammatory disease comprising Myagropsis myagroides extracts or fraction thereof as an effective ingredient | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
KR20130011111A (en) | Pharmaceutical compositions for preventing or treating inflammatory diseases comprising phytosterol compound | |
KR20140128123A (en) | Composition for prevention and treatment of atopic dermatitis and inflammatory disorders comprising extract of Carpesium abrotanoides | |
KR20150115414A (en) | The pharmaceutical compositions for prevention or treatment of inflammatory diseases or promotion of wound healing containing ethylacetate fraction of Schizandra chinensis Baillon | |
KR102085575B1 (en) | Composition for preventing, ameliorating or treating inflammation comprising Siraitia grosvenori residual extract as effective component | |
KR101392333B1 (en) | Pharmaceutical compositions comprising extract or fractions of Rhododendron album Blume for prevention and treatment of inflammatory diseases | |
KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
KR101652317B1 (en) | Medicine, drink and cosmetic composition containing fermented solution of trifoliate orange and starch syrup for preventing, treating or relieving inflammatory diseases or allergic diseases | |
KR101207214B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Glehnia littoralis as an active ingredient | |
KR102510158B1 (en) | Anti-atopic dermatitis composition comprising mixture of plant extract as effective component | |
KR20200069616A (en) | Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi | |
KR20140026091A (en) | Composition comprising mosla chinensis maxim(labiatae) extract for preventing or treating inflammatory allergic disease | |
JP2012158528A (en) | IgE AND IL-4 PRODUCTION INHIBITION COMPOSITION | |
KR101349747B1 (en) | A composition comprising extracts and fractions of Wercklea insignis for prevention and treatment of inflammatory diseases or asthma | |
KR20180100838A (en) | A Composition for Treating or Preventing Inflammatory Diseases Comprising Inhibitors against PI3K and mTOR as an Active Ingredient | |
KR20240054619A (en) | Composition for preventing, improving or treating atopic dermatitis comprising Juncus leschenaultii extract as effective component | |
KR20220106642A (en) | Composition for improving hypersensitivity immune disease comprising Swiss chard extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |